S18 Ep11: Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

Highlights from the PER® CME activity "Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Ruta D. Rao, MD; Kamel Abou Hussein, MD; Jame Abraham, MD, FACP; and Paolo Tarantino, MD, PhD, discuss the data supporting the approvals of next-generation endocrine therapies for ESR1-mutated hormone receptor (HR)–positive, HER2-negative metastatic breast cancer, and how they think through these data when individualizing treatment recommendations for these patients.

Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/hot-seat-which-agent-and-when-integrating-next-generation-endocrine-strategies-into-hrher2-breast-cancer-management-rjgd
This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from Stemline Therapeutics, Inc; and Rigel Pharmaceuticals, Inc..

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.